• Home
  • About Us
  • Technology
  • Pipeline
  • Partnerships
  • News & Publications
HDT Bio

Epithelial Junction Opener Improves Oncolytic Adenovirus Therapy in Mouse Tumor Models — nih.gov

Apr 27, 2016 | Uncategorized

Click here to view...

Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin — nih.gov

May 11, 2015 | Uncategorized

Next Entries »

Recent Posts

  • Providence Swedish Neuroscience Institute (PSNI) Reaches Milestone in Reducing Global Burden of Glioblastoma
  • A New Approach to Treating Brain Cancer: HDT Bio Launches Canadian Clinical Program at McGill University
  • KING5 Seattle Healthlink Feature: Seattle-based group testing new immunotherapy approach to treat deadly form of brain cancer
  • HDT Bio and UTMB Receive MCDC Innovation Prototype Award for Advancing CCHF Vaccine from Lab to Phase 1 Clinical Trial
  • FDA Greenlights HDT Bio’s First-in-Class HDT-321 for the Prevention of Deadly Tick-Borne Disease

Recent Comments

No comments to show.

Privacy Policy

Terms of Use

©2024 HDT Bio

  • Follow
  • Follow